高级检索
当前位置: 首页 > 详情页

Improving tumor hypoxia and radiotherapy resistance via in situ nitric oxide release strategy

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol,Tongji Hosp,Dept Oncol,Wuhan 430030,Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Sch Pharm, Wuhan 430030, Peoples R China [3]Huazhong Univ Sci & Technol,Tongji Hosp,Dept Orthoped,Wuhan 430030,Peoples R China [4]Huazhong Univ Sci & Technol, Natl Engn Res Ctr Nanomed, Wuhan 430030, Peoples R China [5]Huazhong Univ Sci & Technol, Hubei Engn Res Ctr Novel Drug Delivery Syst, Wuhan 430030, Peoples R China
出处:
ISSN:

关键词: Vitamin E TPGS Nitric oxide Angiogenesis Hypoxia Radiotherapy resistance

摘要:
Radiation therapy remains one of the main treatments for cancer. However, conventional radiotherapy not only manifests a low radiation accumulation in the tumor site, but also displays numerous negative effects. The most serious clinical problem is the radiotherapy resistance leading to cancer deterioration. As an important gaseous signal molecule, nitric oxide (NO) has been widely studied for its role in regulating angiogenesis, improving hypoxia, and inhibiting tumor growth. However, due to the unstable characteristic, the application of NO in cancer therapy is still limited. Here, we designed a micellar system formed by a NO donor, D-alpha-Tocopheryl polyethylene glycol 1000 succinate (TPGS)-NO, for enabling sustained NO release to efficiently deliver NO into the tumor area. TPGS-NO could accumulate in the tumor site for extended circulation, thereby releasing NO to exert antitumor effects and enhance radiotherapy effects under low-oxygen conditions. It demonstrated the increased sensitivity of radiotherapy through enhancing tumor angiogenesis appropriately reducing tumor area hypoxia, which significantly induced tumor cell apoptosis and inhibited its repair during radiation. This work may show great potential in synergistic radiotherapy against cancer by facile NO donor administration.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 药学
JCR分区:
出版当年[2018]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol,Tongji Hosp,Dept Oncol,Wuhan 430030,Peoples R China
通讯作者:
通讯机构: [2]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Sch Pharm, Wuhan 430030, Peoples R China [4]Huazhong Univ Sci & Technol, Natl Engn Res Ctr Nanomed, Wuhan 430030, Peoples R China [5]Huazhong Univ Sci & Technol, Hubei Engn Res Ctr Novel Drug Delivery Syst, Wuhan 430030, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:434 今日访问量:0 总访问量:419 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)